[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sechenov University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100648525","mister-study-minimally-invasive-steam-therapy---russian-effectiveness-registry-100648525",false,"NCT07723378","MISTER Study: Minimally Invasive Steam Therapy - Russian Effectiveness Registry","MISTER","Inclusion Criteria\n\n* Lower urinary tract symptoms (IPSS ≥8 points; QoL ≥3 points) due to BPH\n* Prostate volume of 30-150 cm³\n* Qmax ≤15 mL\u002Fs; post-void residual urine volume \\\u003C300 mL\n\nNon-Inclusion Criteria\n\n* Prostate cancer\n* Acute infections of the urinary tract, prostate, or scrotal organs\n* Neurogenic lower urinary tract dysfunction\n* Bladder stone(s)\n* Urethral stricture\n* Prior prostate surgery\n\nExclusion Criteria\n\n* Patient refusal to allow use of medical data for scientific analysis\n* Missing or lost data required for analysis","MALE","18 Years","85 Years",{"count":20,"type":21},1400,"ESTIMATED","INTERVENTIONAL",[24],"NA","Rezūm is a minimally invasive procedure that uses water vapor (steam) to treat urinary symptoms caused by an enlarged prostate (benign prostatic hyperplasia, BPH). It has been used in clinical practice since receiving FDA approval in 2015 and is recommended as a treatment option for men with moderate-to-severe urinary symptoms, including those who wish to preserve ejaculatory function. Clinical trials have shown that Rezūm improves urinary symptoms and flow rates, with benefits that last for at least five years, a low reoperation rate, and a low risk of sexual side effects.\n\nDespite this evidence, several important questions remain. It is not well understood which patients are more likely to experience temporary urinary retention after the procedure, need repeat treatment, or develop ejaculatory changes. Standardized criteria for defining overall treatment success are also lacking.\n\nThe MISTER study is a multicenter registry designed to evaluate real-world outcomes of Rezūm therapy in patients treated in the Russian Federation. Using data from a large patient cohort, the study aims to identify factors associated with urinary retention after catheter removal, the need for repeat treatment or return to medication, and changes in ejaculatory function. The study will also develop and test combined criteria for defining treatment success.",[27,28],"Benign Prostate Hypertrophy(BPH)","LUTS(Lower Urinary Tract Symptoms)",[30,31,32,33],"BPH","LUTS","water vapor thermal ablation","minimally invasive treatment","RECRUITING","2026-07-20",{"date":37,"type":38},"2026-07-23","ACTUAL",{"date":40,"type":21},"2026-08-01",{"date":42,"type":21},"2027-09",{"name":44,"class":45},"Sechenov University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":46},"100580628","safety-and-efficacy-of-milep-versus-standard-eep-100580628","NCT06839768","Safety and Efficacy of MILEP Versus Standard EEP","The MILES Trial: Prospective Randomized Trial of Safety and Efficacy of Minimally-invasive Versus Standard Laser Enucleation of the Prostate","MILES","Inclusion Criteria:\n\nLUTS presence, proven by:\n\n1. IPSS questionnaire (Score \\>20);\n2. OR uroflowmetry result (Qmax \\\u003C10 ml\u002Fs);\n\nExclusion Criteria:\n\n* Prostate volume \\> 120 cc\n* Prostate cancer on pathology;\n* Urethral strictures;\n* Bladder calculi;\n* Prior prostate surgery;\n* Neurogenic bladder dysfunction.",{"count":56,"type":21},340,[24],"Endoscopic enucleation of the prostate (EEP) is a standard treatment for benign prostatic hyperplasia (BPH), with modifications such as MiLEP that utilizes smaller instruments. The reduced resectoscope diameter in MiLEP may help decrease rates of stress urinary incontinence (SUI) and urethral strictures.\n\nObjective: to compare the efficacy and safety of MiLEP and standard EEP with a thulium fiber laser (TFL).",[27,28],"2025-02-17",{"date":62,"type":38},"2025-02-21",{"date":64,"type":38},"2024-03-14",{"date":66,"type":21},"2025-05",{"name":44,"class":45},""]